The Safety and Effectiveness of Zidovudine (AZT) in the Treatment of HIV Infection in Patients With AIDS and Advanced ARC
Status:
Completed
Trial end date:
1989-03-01
Target enrollment:
Participant gender:
Summary
To obtain information about the long-term safety and toxicity of zidovudine (AZT). To
ascertain whether interruption/resumption at a lower dosage is the optimal management of AZT
toxicity.
Because of the high incidence of toxicity and the relatively short-term follow-up of the
patients due to the early ending of the Phase II placebo-controlled experiment, it is
valuable to continue to get information on the long-term toxicity of AZT.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)